Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesCompany aims to accelerate access to much-needed biosimilar to reference ...

Tofidence is indicated in certain patients for the treatment of moderate to severe rheumatoid arthritis, giant cell arteritis ...

Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...